Streptococcus and STI Unit, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Servicio de Enfermedades deTransmisión Sexual, Centro Nacional de Referencia en ITS, INEI-ANLIS 'Dr. Carlos G. Malbrán', Buenos Aires, Argentina.
Sex Transm Infect. 2018 Nov;94(7):479-482. doi: 10.1136/sextrans-2017-053502. Epub 2018 Apr 19.
A antimicrobial susceptibility quality control comparison programme was re-established in Latin America and the Caribbean to ensure antimicrobial susceptibility data produced from the region are comparable nationally and internationally.
Three panels, consisting of isolates comprising reference strains and other characterised isolates were sent to 11 participating laboratories between 2013 and 2015. Antimicrobial susceptibilities for these isolates were determined using agar dilution, Etest or disc diffusion methods. Modal minimum inhibitory concentrations (MICs) for each panel isolate/antibiotic combination were calculated. The guidelines of the Clinical and Laboratory Standards Institute were used for interpretations of antimicrobial susceptibility. The agreement of MICs with the modal MICs was determined for each of the participating laboratories as well as for each of the antibiotics tested.
Five of 11 laboratories that participated in at least one panel had an overall average agreement between participants' MIC results and modal MICs of >90%. For other laboratories, agreements ranged from 60.0% to 82.4%. The proportion of agreement between interpretations for all the antibiotics, except penicillin and tetracycline, was >90%. The percentages of agreement between MIC results and their modes for erythromycin, spectinomycin, cefixime and azithromycin were >90%. Tetracycline, ceftriaxone and ciprofloxacin agreement ranged from 84.5% to 89.1%, while penicillin had 78.8% agreement between MICs and modal MICs.
The participating laboratories had acceptable results, similar to other international quality assurance programmes. It is important to ensure continuation of the International Gonococcal Antimicrobial Susceptibility Quality Control Comparison Programme to ensure that participants can identify and correct any problems in antimicrobial susceptibility testing for as they arise and continue to generate reproducible and reliable data.
在拉丁美洲和加勒比地区重新建立了一个抗菌药物敏感性质量控制比较计划，以确保该地区产生的抗菌药物敏感性数据在国家和国际上具有可比性。
2013 年至 2015 年期间，向 11 个参与实验室发送了三个包含参考菌株和其他特征菌株的分离株的小组。使用琼脂稀释法、Etest 或纸片扩散法测定这些分离株的抗菌药物敏感性。计算每个小组分离株/抗生素组合的模式最小抑菌浓度（MIC）。采用临床和实验室标准协会的指南来解释抗菌药物敏感性。确定了每个参与实验室以及每个测试抗生素的 MIC 与模式 MIC 的一致性。
至少参加了一个小组的 11 个实验室中的 5 个实验室的参与者 MIC 结果与模式 MIC 的总体平均一致性>90%。对于其他实验室，一致性范围为 60.0%至 82.4%。除青霉素和四环素外，所有抗生素的解释一致性比例>90%。红霉素、壮观霉素、头孢克肟和阿奇霉素的 MIC 结果与模式之间的一致性百分比>90%。四环素、头孢曲松和环丙沙星的一致性范围为 84.5%至 89.1%，而青霉素的 MIC 与模式 MIC 的一致性为 78.8%。
参与实验室的结果可接受，与其他国际质量保证计划相似。重要的是要确保继续进行国际淋球菌抗菌药物敏感性质量控制比较计划，以确保参与者能够在出现问题时识别和纠正抗菌药物敏感性测试中的任何问题，并继续生成可重复和可靠的数据。
